Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-masked, placebo-controlled, cross-over, 32 weeks study

Trial Profile

Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-masked, placebo-controlled, cross-over, 32 weeks study

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Infliximab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association.
    • 22 Apr 2010 Results published in Diabetes Care.
    • 19 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top